12 completed, 9 recruiting, 5 not yet recruiting, 5 unknown. 11 Phase 3, 8 Phase 2, 7 Not applicable, 6 Phase 4, 1 Phase 1.
Follow Colchicine 0.5 MG: new trials by email Literature Review of Colchicine 0.5 MG trials Research Report on Colchicine 0.5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage Colchicine 0.5 MG, Placebo - Colchicine, ICH - Intracerebral Hemorrhage | Phase 3 | Not yet recruiting | Population Health Research Institute | 1125 | 2026-09-30 | 2026-09-01 |
| Low-dose Colchicine for CABG Graft Failure Prevention Colchicine Pill, Placebo - CAD - Coronary Artery Disease, CABG | Not applicable | Not yet recruiting | Beijing Anzhen Hospital | 622 | 2026-09-01 | 2026-05-06 |
| A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W - Gout Arthritis | Phase 2 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 200 | 2026-08-02 | 2026-07-20 |
| Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG, Placebo Rivaroxaban - Ischemic Stroke | Phase 4 | Not yet recruiting | Brazilian Clinical Research Institute | 4500 | 2026-07-01 | 2026-02-11 |
| Colchicine to Reduce Coronary Artery Inflammation in People With HIV Colchicine 0.5 mg, Placebo - HIV Infection, Cardiovascular Diseases (CVD) | Phase 2 | Recruiting | Instituto de Investigación Hospital Universitario La Paz | 90 | 2026-06-01 | 2026-07-15 |
| Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX) Colchicine 0.5 mg, Placebo colchicine - Stroke | Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 7500 | 2025-07-04 | 2025-06-27 |
| Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group - Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Recruiting | Hospital do Coracao | 7713 | 2025-06-12 | 2026-01-22 |
| Colchicine And Dialysis Patients; a Feasibility Study Colchicine 0.5 mg - Haemodialysis Patients, Colchicine | Not applicable | Recruiting | King's College London | 100 | 2025-04-10 | 2026-08-13 |
| The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL Colchicine 0.5 mg, Deferoxamine Mesylate, Control (Standard treatment) - Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage | Phase 3 | Recruiting | The George Institute | 2000 | 2025-02-27 | 2026-07-08 |
| The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery NSAID, Colchicine 0.5 MG - Coronary Artery Disease, Atrial Fibrillation | Phase 4 | Completed | Tomsk Cardiology Research Institute | 140 | 2025-01-20 | 2026-09-30 |
| Treatment of ACuTe Coronary Syndromes With Low-dose colchICine Colchicine Pill, Placebo - Acute Coronary Syndrome, Unstable Angina | Not applicable | Recruiting | Beijing Anzhen Hospital | 6574 | 2024-09-02 | 2024-10-30 |
| Efficacy and Safety of Colchicine After PCI Colchicine 0.5 mg, Colchicine 0.375 mg, Placebo - Coronary Heart Disease, Percutaneous Coronary Intervention | Phase 3 | Active not recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 8862 | 2024-07-09 | 2026-09-03 |
| ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes Colchicine 0.5 MG - Coronary Artery Disease | Phase 3 | Unknown | King's College Hospital NHS Trust | 50 | 2024-06-24 | 2024-06-21 |
| A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, Colchicine 0.5 mg - Gout Arthritis | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 157 | 2024-03-30 | 2024-08-05 |
| COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease Colchicine 0.5 MG, Colchicine placebo, Thiamine Mononitrate 300 mg - Heart Failure | Phase 3 | Recruiting | Hamilton Health Sciences Corporation | 2500 | 2024-01-29 | 2026-10-02 |
| Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery Colchicine 0.5 MG, Placebo - Inflammatory Response, Cardiac Disease | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 768 | 2024-01-28 | 2025-11-17 |
| Different Doses of Colchicine on hsCRP Colchicine 0.5 MG, Colchicine 0.375 MG, Colchicine 0.25 MG - Coronary Artery Disease, Percutaneous Coronary Intervention | Phase 4 | Completed | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2023-10-10 | 2024-04-16 |
| COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE) Colchicine 0.5 MG - Ischemic Stroke, Atherosclerosis | Phase 2 | Unknown | University College Dublin | 91 | 2023-10-01 | 2023-10-02 |
| Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis Colchicine 0.5 MG, Ticagrelor 90mg, Aspirin 75-300mg - Stroke, Stroke, Ischemic | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2800 | 2023-05-17 | 2025-09-08 |
| Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Colchicine 0.5 MG - Coronary Artery Disease | Phase 4 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 84 | 2023-03-15 | 2024-10-15 |
Showing 20 of 33. Sign in to see all of them.
Coronary Artery Disease (7) · COVID-19 (5) · Stroke (5) · Atherosclerosis (4) · Inflammation (3) · Ischemic Stroke (3) · Angina, Unstable (2) · Arthritis, Gouty (2) · Cerebral Hemorrhage (2) · Coronavirus Infections (2) · Heart Diseases (2) · Heart Failure (2) · Acute Coronary Syndrome (1) · Atrial Fibrillation (1) · Cardiovascular Diseases (1)
Ain Shams University (2) · Beijing Anzhen Hospital (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Tiantan Hospital (1) · Brazilian Clinical Research Institute (1) · Chinese University of Hong Kong (1) · ClinAmygate (1) · Donders Centre for Cognitive Neuroimaging (1) · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (1) · Fundación Universitaria de Ciencias de la Salud (1) · Hamilton Health Sciences Corporation (1) · Hawler Medical University (1)
China (7) · Egypt (3) · Brazil (2) · Iraq (2) · Spain (2) · Australia (1) · Canada (1) · Colombia (1) · Denmark (1) · France (1) · Hong Kong (1) · Ireland (1) · Israel (1) · Japan (1) · Netherlands (1)
Ahmed S Abdulamir, MD (1) · Aristeidis Katsanos, MD (1) · Aryan MF Jalal (1) · Ashkan Shoamanesh, MD (1) · Dashty Albustany, MBChB.FRCP (1) · Domingo Pascual Figal, MD (1) · DongJin Wang, M.D (1) · Dr Michael Robson (1) · Emad Issak (1) · Erlon Oliveira de Abreu-Silva, M.D (1) · Esther Aarts, Prof.dr. (1) · Hejian Zou, MD (1)
PMID 34658014, PMID 16439323, PMID 31986264, PMID 32020029, PMID 32176778, PMID 32346093, PMID 33769515, PMID 37558377, PMID 38251589, PMID 39029568, PMID 39266309, PMID 40868251, PMID 41670023